In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin
- 1 August 1996
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 15 (8) , 678-682
- https://doi.org/10.1007/bf01691159
Abstract
The activity of the new fluoroquinolone trovafloxacin (CP-99,219) was compared with that of ciprofloxacin and ofloxacin against 517 bacterial isolates representing 50 different species. Against members of the family Enterobacteriaceae, all three drugs showed good in vitro activity. Against most anaerobic bacteria, Staphylococcus, Streptococcus, and Enterococcus species, trovafloxacin was four- to sixteenfold more active than ciprofloxacin. For disk diffusion testing, 10 mu g trovafloxacin disks gave satisfactory results. Tentative criteria are proposed for use during clinical studies.Keywords
This publication has 6 references indexed in Scilit:
- Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methodsDiagnostic Microbiology and Infectious Disease, 1994
- In vitro activity of the new fluoroquinolone CP-99,219Antimicrobial Agents and Chemotherapy, 1994
- Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobesAntimicrobial Agents and Chemotherapy, 1994
- In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1993
- In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridoneAntimicrobial Agents and Chemotherapy, 1993
- Susceptibility Tests of Anaerobic Bacteria: Statistical and Clinical ConsiderationsThe Journal of Infectious Diseases, 1974